Workflow
联环药业: 联环药业投资者关系活动记录表

Group 1: R&D Strength and Innovation - The company is enhancing its technological innovation efforts by establishing multiple R&D platforms in Nanjing and Yangzhou, supported by academicians and provincial engineering technology centers [1][2] - The company has six innovative drugs in development, focusing on cardiovascular, urology, oncology, and respiratory systems, with one drug in Phase III and two in Phase I clinical trials [2][3] Group 2: Core Innovative Drug Pipeline - LH-1801, developed in collaboration with the Shanghai Institute of Materia Medica, targets Type 2 diabetes and is part of a treatment matrix for metabolic diseases [2] - LH-1901, an inhalation drug approved for clinical trials in September 2024, aims to fill a gap in the respiratory field with superior efficacy [2] - LH-2103, submitted for clinical application in January 2025, is expected to strengthen the company's position in the urology market [2] Group 3: Sales Performance and Market Strategy - The company's product Aipulete has shown strong market performance, with sales volume reaching 11.89 million tablets in 2024, a 30.28% increase from the previous year [3] - The company is focusing on professional and academic promotion strategies to expand product influence and brand recognition [3] Group 4: Export and Internationalization - The company exports mainly raw materials to markets in North America, Eastern Europe, Southeast Asia, South America, and Oceania, with a focus on long-term international strategies [4] - The establishment of Unioncle Pharma LLC in the U.S. aims to facilitate international collaboration and accelerate the registration of R&D products abroad [4] Group 5: Market Integration and Operational Efficiency - The company is implementing a strategy of "three integrations and one transformation" to enhance marketing team professionalism and drive sales through multiple channels [5] - Investments in automation and digital transformation are aimed at improving collaboration across R&D, sales, and production [5][6] Group 6: Financial and Capital Operations - The company is focusing on mergers and acquisitions to enhance its resource integration and improve its capital structure [6][9] - Recent capital increases in subsidiaries are intended to strengthen core competitiveness and support overall strategic goals [7][8]